Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Clinical Trials
Three phase II clinical trials to evaluate anticancer compound ZK-EPO
January 5th, 2006
Schering AG, Germany (SHR) announced the start of three phase II studies in Europe evaluating its fully synthetic epothilone, ZK-EPO, for the treatment of several types of cancers such as non-small cell lung cancer, ovarian cancer and breast cancer. The clinical trials will assess ZK-EPO's safety and efficacy in each of these cancer types. ZK-EPO is a fully synthetic epothilone in clinical development. It is designed to improve efficacy and safety compared to the chemotherapies currently available. In non-small cell lung cancer, a multicenter study is currently enrolling patients in Germany. The trial is designed to examine the...
Source: Women's Health Weekly (2006-01-05)
|
